Education Program
Description:
Many therapeutic progresses have been made in recent years in the field of indolent lymphoma. Beside different classical cytotoxic agents, immunotherapies have continued to develop, with new agents and new combinations recently approved. Several kinase inhibitors have been evaluated in follicular and marginal zone lymphomas, and are now available for patients, and other forms of targeted therapies are currently being investigated. All of these approaches may have specific side effects, potentially impairing patient quality of life. While these diseases are often chronic, patients overall survival has been significantly improved in the last 20 years and some of them may enjoy long periods without any treatment, and eventually be considered as cured. Others present with difficult to treat disease, refractory to multiple therapies, and histologic transformation has been usually considered as a turning point in the disease history, when other therapeutic approaches need to be implemented.
Dr. Gilles Salles will review different therapeutic options currently available for the first line or subsequent progressions in patients with follicular lymphoma, and discuss how to optimize the use of the different approaches.
Dr. Pier Luigi Zinzani will discuss the different clinical presentations of marginal zone lymphoma and address their therapeutic management. He will also address how new agents or combinations developed in the field could be used for those patients.
Dr. Sonali Smith will review the current data available for patients with transformed indolent lymphoma, and discuss the respective role of cytotoxic agents, transplant and CAR-T cells in this setting.
Chair:
Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud
Disclosures:
Salles: Karyopharm: Consultancy; Kite: Consultancy, Honoraria, Other; MorphoSys: Consultancy, Honoraria, Other; Abbvie: Consultancy, Honoraria, Other: Participation in educational events; Genmab: Consultancy; Debiopharm: Consultancy; F. Hoffman-La Roche Ltd: Consultancy, Honoraria, Other; Takeda: Consultancy, Honoraria, Other; Gilead: Consultancy, Honoraria, Other: Participation in educational events; Janssen: Consultancy, Honoraria, Other: Participation in educational events; Epizyme: Consultancy; Novartis: Consultancy, Honoraria, Other; Bristol Myers Squibb: Consultancy, Other; Celgene: Consultancy, Honoraria, Other: Participation in educational events; Autolus: Consultancy; Amgen: Honoraria, Other: Participation in educational events.
Panelists:
Gilles Salles, MD, PhD, Centre Hospitalier Lyon-Sud
,
Pier Luigi Zinzani, MD, PhD, University of Bologna
and
Sonali M. Smith, MD, University of Chicago
Disclosures:
Salles: Novartis: Consultancy, Honoraria, Other; MorphoSys: Consultancy, Honoraria, Other; Bristol Myers Squibb: Consultancy, Other; F. Hoffman-La Roche Ltd: Consultancy, Honoraria, Other; Kite: Consultancy, Honoraria, Other; Amgen: Honoraria, Other: Participation in educational events; Autolus: Consultancy; Karyopharm: Consultancy; Celgene: Consultancy, Honoraria, Other: Participation in educational events; Debiopharm: Consultancy; Genmab: Consultancy; Gilead: Consultancy, Honoraria, Other: Participation in educational events; Epizyme: Consultancy; Abbvie: Consultancy, Honoraria, Other: Participation in educational events; Janssen: Consultancy, Honoraria, Other: Participation in educational events; Takeda: Consultancy, Honoraria, Other. Zinzani: BMS: Honoraria, Speakers Bureau; KIRIN KYOWA: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; VERASTEM: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ROCHE: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SERVIER: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; TAKEDA: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC THERAPEUTICS: Honoraria, Membership on an entity's Board of Directors or advisory committees; AUTOLUS: Honoraria, Membership on an entity's Board of Directors or advisory committees; HIKMA: Honoraria, Speakers Bureau; BEIGENE: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ASTRAZENECA: Honoraria, Membership on an entity's Board of Directors or advisory committees; TG THERAPEUTICALS: Honoraria, Membership on an entity's Board of Directors or advisory committees; BAYER: Honoraria, Membership on an entity's Board of Directors or advisory committees; INCYTE: Honoraria, Speakers Bureau; MEI PHARMA: Honoraria, Membership on an entity's Board of Directors or advisory committees; KARYOPHARM: Honoraria, Membership on an entity's Board of Directors or advisory committees; ASTELLAS: Honoraria, Speakers Bureau; CELLTRION: Honoraria, Speakers Bureau; JANSSEN: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EUSAPHARMA: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; DEBIOPHARMA: Honoraria; GILEAD: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ABBVIE: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MERCK: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Smith: Acerta: Research Funding; Janssen: Consultancy; BMS: Consultancy; Karyopharm: Consultancy, Research Funding; FortySeven: Research Funding; Genentech/Roche: Consultancy, Other: Support of parent study and funding of editorial support, Research Funding; TG Therapeutics: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Pharmacyclics: Research Funding.
Many therapeutic progresses have been made in recent years in the field of indolent lymphoma. Beside different classical cytotoxic agents, immunotherapies have continued to develop, with new agents and new combinations recently approved. Several kinase inhibitors have been evaluated in follicular and marginal zone lymphomas, and are now available for patients, and other forms of targeted therapies are currently being investigated. All of these approaches may have specific side effects, potentially impairing patient quality of life. While these diseases are often chronic, patients overall survival has been significantly improved in the last 20 years and some of them may enjoy long periods without any treatment, and eventually be considered as cured. Others present with difficult to treat disease, refractory to multiple therapies, and histologic transformation has been usually considered as a turning point in the disease history, when other therapeutic approaches need to be implemented.
Dr. Gilles Salles will review different therapeutic options currently available for the first line or subsequent progressions in patients with follicular lymphoma, and discuss how to optimize the use of the different approaches.
Dr. Pier Luigi Zinzani will discuss the different clinical presentations of marginal zone lymphoma and address their therapeutic management. He will also address how new agents or combinations developed in the field could be used for those patients.
Dr. Sonali Smith will review the current data available for patients with transformed indolent lymphoma, and discuss the respective role of cytotoxic agents, transplant and CAR-T cells in this setting.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.